Richard Armstrong (@VisionaryProp) header
Richard Armstrong (@VisionaryProp) profile picture

Specialist Property Finding for the Catastrophically Injured. Expert witness reports.

Alderley Edge
Joined July 2012
Photo by Richard Armstrong (@VisionaryProp)Photo by Richard Armstrong (@VisionaryProp)Photo by Richard Armstrong (@VisionaryProp)Photo by Richard Armstrong (@VisionaryProp)Photo by Richard Armstrong (@VisionaryProp)Photo by Richard Armstrong (@VisionaryProp)Photo by Richard Armstrong (@VisionaryProp)Photo by Richard Armstrong (@VisionaryProp)Photo by Richard Armstrong (@VisionaryProp)Photo by Richard Armstrong (@VisionaryProp)
Richard Armstrong retweeted
It feels like late 2019 / early 2020 all over again for @avacta #AVCT. I believe the share price sits on the cusp of a monumental breakout. To fully appreciate the extraordinary asymmetric opportunity here, investors need to work through four sequential topics. 1) The science. A best-in-class delivery platform for treating the large majority of all cancer cases. It takes time to get one’s head around the sheer scale of what Avacta has already achieved with pre|CISION, and how the platform vastly outperforms the various competing technologies and modalities in targeted oncology, in a plethora of ways. 2) Potential value. If you have gotten to grips with 1) above, you will be able to appreciate that there’s a genuine possibility of Avacta’s first Gen2 and Gen3 assets - AVA6103 and AVA6207 - becoming all-time best-selling oncology drugs – and consequently, of Avacta surpassing the leading targeted oncology companies / acquisitions (Revolution, Seagen, etc.) in value over the next 2-3 years. 3) Understanding why a chronic undervaluation has persisted. There are three key matters to consider here: i) the LSE is a shadow of its former self, the UK investment community struggling. ii) the Avacta retail base has been subject to intense share price volatility and consequently suffers from a severe case of PTSD. iii) the development of the pre|CISION platform by a hitherto little-known AIM-listed company appears to be a too-good-to-be-true story, for those who have not looked closely. 4) Understanding why this undervaluation is unlikely to last much longer. Next month, we’ll see the first biopsy data for AVA6103. In the first few months of next year, we’ll start to receive efficacy data from the trial. These are critical landmarks for the company: it will open the market’s eyes to the gulf in ability (and value) between Avacta’s Gen1 platform and Gen2 platform. A partnership for AVA6000 (free carry from end P1b through to sales, ideally) would also be a major boost, as would a platform out-licensing deal that could bring in a sizeable cash injection. Finally, a dual NASDAQ listing (hopefully to be announced in the next several months) would (in my view) also be very well received by the market, to combat 3) i) above. I intend to post detailed notes on each of the above four topics, shortly. I envy (intensely!) those who can today buy a big chunk of AVCT for the very first time, at 57p. The platform has been enormously derisked the past six months, yet the share price has reacted negatively in that timeframe. I simply cannot see this status quo lasting much longer. The upside in the relatively near-term is just too vast, relative to the current mkt cap.
11
19
2
217
13,146
Richard Armstrong retweeted
Say what you want about Donald Trump, but when it comes to being a piece of shit without a single redeeming quality, he has no competition.
114
424
3
4,363
26,243
Every Avacta shareholder should read this CAREFULLY…….#AVCT
#AVCT raised at 68p (just a few weeks ago, with directors taking £660k while sat on biopsies) to get them through the most important data period (I.e. now). Here’s a simple illustration of how crazed the dilution debate has become: Scenario 1 - place £12.5m @ 68p = 18.3m shares Scenario 2 - place £12.5m @ 85p = 14.7m shares Say AVCT was sold for £2Bn next week. Pure hypothetical and had 475m in issue: 475m + 18.3m = 493.3m shares 475m + 14.7m = 489.7m shares — £2Bn / 493.3m = 405p per share £2Bn / 489.7m = 408p per share — Had they placed at 85p, it would have been hailed as the perfect strategy, by the same people lamenting 68p…🤪 The difference is 3 pence on a £2Bn takeover. People really do need to get a grip. Avacta has until late May 2027 to deal across a number of assets. I count three: 6000 6207 preCISION to a 3rd party warhead A lot can happen with AVA6103 data over the next few weeks. All of that feeds the value of 6207 and licensing preCISION to a 3rd party asset. Regardless of whether the 6207 warhead has an owner (or ownership is about to expire) all the know-how sits with the pharma who took the drug through clinic. That’s the valuable bit. No chance they seek to do it alone.
3
43
4,536
Richard Armstrong retweeted
Pay rise for whoever sent this out from Sky News. Beautiful wording.
12
584
5
18,580
302,452
Richard Armstrong retweeted
I find it amazing that all of the people citing ‘hearsay’ as a reason to discount evidence against Brand, think they have a more acute legal mind than Brand’s defence team, whom at no point raised this themselves. #RussellBrand #rapist
5
2
38
765
Richard Armstrong retweeted
Witkoff and Kushner. Two unelected pieces of shit with no democratic mandate, sitting down with a war criminal as though they have the authority to negotiate. This should fucking enrage everyone.
813
5,627
197
21,471
227,283
Richard Armstrong retweeted
“ I am today resigning as Microsoft’s head of international outage protection”
103
716
23
6,697
84,296
Here’s a man who knows he will soon be employed by Big Pharma - and also knows his commute won’t change ! #AVCT
4
12
88
3,635
Richard Armstrong retweeted
#AVCT Did you see that smile from Ruairidh?! (Bear in mind they have biopsies in hand) 💥💥💥
5
27
3
94
10,148
Richard Armstrong retweeted
#AVCT I agree, Tom & Benny. Long-term investors have funded the scientific progress, but I also think we’re at a tipping point where the AVA6103 data will be compelling and put us even more firmly on pharma companies’ radar. We are entering the cannot be ignored disrupt zone. Small biotech companies like Avacta, with potentially groundbreaking science, should be protected and nurtured. Shorting small pharma and life science companies should, IMO, be banned. I regard it as an abhorrent form of sabotage. Regardless of my investment in Avacta, I would still think TW et al are scumbags.
3
5
63
1,870
You were told. Seen this fleecing too many times before. So many geared shareholders taken out just as #AVCT’s second drug is in its golden efficacy zone. Amazing how gullible some people can be. Fear & greed are powerful tools when the Market Makers use them against you. Avacta is off to the stars. AVA6103 ‘sure bet’ as per the CEO. Think about the magnitude of that statement. It will equate into a Biblical bounce
This is the greatest gift that #avct investors or (dare I say it) traders will ever see. On the Daily chart the RSI is down to 19.7 - last time it hit this level the stock bounced 50% in no time. Bookmark this tweet - this time will be no different
1
2
39
2,113
Richard Armstrong retweeted
The man who invented Benylin was buried last week. As a mark of respect there was no coffin at his funeral.
18
8
5
168
5,927
Happy to report that after day after day of huge shapes in the auctions the uncrossing trade was at 54p on volume of 18,647 shares SHENANIGANS complete 52p was the low today Any bets on the pre Christmas-high? #avct #firsttimeinalongtime #Trendreversal
4
2
40
4,066
Richard Armstrong retweeted
As I digest the millionth opinion on #AVCT I am reminded (Stanley Druckenmiller) the best way to make obscene amounts of money is buying an idea which is not popular today but what will be popular tomorrow. AVA6103 is the on cusp of that revolution. Churning out data - right now - which will define how toxic chemotherapies are delivered safely tomorrow. I don’t think even the staunchest advocates realise the magnitude of what AVCT is sat on right now in AVA6103: “A remarkable alignment of pre-clinical and clinical data” “The best (Coughlin) has seen in over two decades” A “sure bet”. It works. Enormous value is inevitable if you can detach from the artificial noise.
4
15
111
3,892
Every single time the mass trolling and FUD stops with #Avct you know that a reversal is coming. As predictable as night follows day - and all (like the last times) totally orchestrated. The Directors happily paid up for a million shares at 68p - at this level here's your Christmas present. So much to be announced in the next weeks. And never forget - the data which is rolling right now will dictate the value of ALL the deals on the table.
3
5
64
3,958
Richard Armstrong retweeted
I reckon Guy Fawkes plan to blow up Parliament on November 5th was kind of genius because people wouldn't notice the explosions, what with all the fireworks going off & all.
83
1,171
47
32,106
662,433
This is the greatest gift that #avct investors or (dare I say it) traders will ever see. On the Daily chart the RSI is down to 19.7 - last time it hit this level the stock bounced 50% in no time. Bookmark this tweet - this time will be no different
6
3
1
79
6,456
🚨Cheshire East Council just painted poppies on the roads to honour our fallen. Meanwhile half the country’s councils are busy erasing history, renaming streets, and lecturing everyone about ‘diversity’. One council still remembers who built and defended this country. The rest are busy apologising for it.
91
440
26
2,044
26,737
Richard Armstrong retweeted
Guy behind me at the traffic lights, beeping your horn and giving me the wanker sign isn’t going to make me type this tweet any faster.
51
696
14
22,439
247,612
As true now as the day she said it......
Reposting this for no particular reason Liz Cheney: “I say this to my Republican colleagues who are defending the indefensible. There will come a day when Donald Trump is gone, but your dishonor will remain.”
277